RT Journal Article
T1 Elevated levels of serum CDCP1 in individuals recovering from severe COVID-19 disease.
A1 Blanco, Jose-Ramon
A1 Cobos-Ceballos, Maria-Jesus
A1 Navarro, Francisco
A1 Sanjoaquin, Isabel
A1 Armiñanzas, Carlos
A1 Bernal, Enrique
A1 Buzon-Martin, Luis
A1 Viribay, Miguel
A1 Perez-Martinez, Laura
A1 Espejo-Perez, Simona
A1 Valencia, Borja
A1 Guzman-Aguilar, Jesus
A1 Ruiz-Cubillan, Juan-Jose
A1 Alcalde, Consuelo
A1 Gutierrez-Herrero, Fernando Gustavo
A1 Olalla, Julian
A1 Andres-Esteban, Eva-Maria
A1 Jurado-Gamez, Bernabe
A1 Ugedo, Javier
K1 CDCP1
K1 COVID-19
K1 Biomarkers
K1 Recovery
AB COVID-19 survivors report residual lung abnormalities after discharge from the hospital. The aim of this study was to identify biomarkers in serum and induced sputum samples from patients after hospitalization for COVID-19. Patients admitted to hospitals in Spain with laboratory-confirmed COVID-19 were recruited for this study. SARS-CoV-2-infected patients were divided into groups with mild/moderate and severe disease according to the severity of their symptoms during hospitalization. Levels of 92 biomarkers were measured in serum and induced sputum samples. A total of 108 patients (46.2% severe cases) were included in this study. The median number of days after the onset of symptoms was 104. A significant difference was observed in diffusing capacity for carbon monoxide (DLCO), an indicator of lung function, whereby DLCO  Higher levels of CDCP1 remain after hospital discharge and are associated with the severity of COVID-19. The possible prognostic implications warrant further investigation.
PB Impact Journals LLC
YR 2022
FD 2022-02-08
LK http://hdl.handle.net/10668/21745
UL http://hdl.handle.net/10668/21745
LA en
NO Blanco JR, Cobos-Ceballos MJ, Navarro F, Sanjoaquin I, Armiñanzas C, Bernal E, et al. Elevated levels of serum CDCP1 in individuals recovering from severe COVID-19 disease. Aging (Albany NY). 2022 Feb 16;14(4):1597-1610
DS RISalud
RD Apr 17, 2025